DIBASE ® is a cholecalciferol-based drug
THERAPEUTIC GROUP: Vitamin D
Indications DIBASE ® - Cholecalciferol
DIBASE ® is used in the prevention and treatment of pathologies associated with vitamin D deficiency.
Mechanism of action DIBASE ® - Cholecalciferol
Cholecalciferol, commonly referred to as vitamin D3, is a steroid derived from dehydrocholesterol following exposure to ultraviolet radiation, a precursor of the biologically active form of vitamin D known as calcitriol.
This steroid, suitably bound in the circulation to specific plasma proteins, first reaches the liver for a first hydroxylation and then the kidney, where it is converted into 1, 25 dihydroxy cholecalciferol, then made functionally active.
The vitamin thus hydroxylated can act on various tissues through specific nuclear receptors, finely regulating the calcium-phosphorus metabolism and more precisely by increasing the renal reabsorption and intestinal absorption of these elements.
However, the steroid nature of this vitamin and the ability to regulate gene expression, in a very similar way to what different hormones do, has invited the various research groups to better investigate the biological and pharmacodynamic characteristics of this element, bringing out entirely new therapeutic properties comparable to those of some growth factors.
Studies carried out and clinical efficacy
1.VITAMIN D AND VASCULAR HEALTH
Nephrology (Carlton). 2011 Dec 19.
Nutritional vitamin D supplementation in hemodialysis: a potential vascular benefit?
Assimon MM, Salenger PV, El-Fawal HA, Mason DL.
The administration of vitamin D in patients undergoing hemodialysis has proved particularly useful in reducing some factors promoting atherosclerosis such as the expression of vascular adhesion molecules and pro-inflammatory cytokines.
2. VITAMIN D IN THE DENTAL SECTOR
Clin Oral Implants Res. 2011 Sep 5
The potential effects of cholecalciferol on bone regeneration in dogs.
Hong HH, Chou TA, Yang JC, Chang CJ.
Experimental dental study that demonstrates how supplementation with vitamin D and calcium can be positive in favoring mandibular and maxillary bone regeneration, improving the outcomes of oral surgical implant prosthesis therapy.
3. VITAMIN D3 AND "ALL" INSULIN SENSITIVITY
Transl Res. 2011 Nov; 158: 276-81. doi: 10.1016 / j.trsl.2011.05.002. Epub 2011 Jun 7.
Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose.
Nazarian S, St Peter JV, Boston RC, Jones SA, Mariash CN.
Study demonstrating how high-dose oral administration of vitamin D3 can improve insulin sensitivity in patients with impaired fasting glycaemia, thus delaying the progression of severe metabolic diseases such as diabetes.
Method of use and dosage
DIBASE ®
Oral drops of 10,000 IU / ml of cholecalciferol;
oral solution of 25,000 IU / 2.5 ml of cholecalcifer;
solution for injection of 100,000 - 300,000 IU / ml of cholecalciferol:
the dosage and the therapeutic scheme vary considerably depending on the formulation used.
In general, the 100,000 IU injectable solutions should be taken once every 4 - 6 months, the 300,000 IU solution once a year, and the 25,000 IU solution once a month.
The oral drops, on the other hand, adapt perfectly to daily or weekly administration, allowing a fine modulation of the dosage.
In any case, the definition of the therapeutic procedure is up to the doctor after having carefully evaluated the patient's state of health.
DIBASE ® warnings - Cholecalciferol
Treatment with DIBASE ® should be preceded and accompanied by periodic monitoring of the blood and urinary concentrations of calcium and phosphorus, in order to avoid the onset of hypercalcemia and related pathologies.
At the same time it is important to supervise renal function, which is important both in ensuring the correct biological and therapeutic functionality of cholecalciferol and in properly regulating calcium / phosphorus metabolism.
PREGNANCY AND BREASTFEEDING
The side effects on the health of the fetus described following the administration of high doses of vitamin D3, lead the doctor to administer this drug only in cases of real need, where the benefits would be significantly more important than the risks.
On the other hand, it is not recommended to take DIBASE ® during the period of breastfeeding, given the ability of this fat-soluble vitamin to easily pass through the breast filter, thus concentrating in breast milk.
Interactions
The administration of DIBASE ® should take place with particular care in patients undergoing concomitant therapy with antiepileptics and anticonvulsants such as barbiturates, given the ability of these active ingredients to reduce the effect of vitamin D3.
The same attention should be paid to patients undergoing digitalis therapy, whose intake together with that of vitamin D3 could increase the risk of hypercalcemia and its effects on heart rhythm.
Contraindications DIBASE ® - Cholecalciferol
DIBASE ® is contraindicated in case of hypercalcemia, renal insufficiency, nephrolithiasis and hypersensitivity to the active substance or to one of its excipients.
Undesirable Effects - Side Effects
Although cholecalciferol therapy has been found to be well tolerated if carried out according to appropriate medical indications, it is not possible to exclude the occurrence of some adverse reactions such as nausea, diarrhea, anorexia, weight loss, polyuria, sweating, headache, thirst, dizziness, hypercalcemia, hypercalciuria and hyperphostataemia with related complications, especially following prolonged or high-dose therapies.
Note
DIBASE ® can only be sold under strict medical prescription.
The information on DIBASE ® - Cholecalciferol published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
